Every 10-Q that The Pennant Group, Inc. (PNTG) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow PNTG and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PNTG filings page.
The Pennant Group, Inc. reported higher Q2 2026 results, with revenue of 297,984 (in thousands) versus 219,501 (in thousands) a year earlier and income from operations of 17,186 (in thousands). Net income attributable to Pennant was 9,082 (in thousands), or diluted EPS of $0.25.
For the first six months, revenue was 583,348 (in thousands) and net income attributable to Pennant was 17,601 (in thousands). Medicare and Medicaid together represented 64.3% of Q2 revenue. Home health and hospice produced 237,353 (in thousands) of Q2 revenue, senior living 58,497 (in thousands), and Segment Adjusted EBITDAR from Operations totaled 56,913 (in thousands).
Total assets were 1,037,291 (in thousands) at June 30, 2026, including a new equity method investment of 28,798 (in thousands). Long-term debt was 198,500 (in thousands) under an amended credit facility and term loans, with a weighted average interest rate of 5.88%. Operating cash flow for the first half was 18,425 (in thousands), while significant investing outflows reflected acquisitions and the equity method investment. The company also outlines new CMS hospice and home health reimbursement updates, a nationwide enrollment moratorium for new hospices and home health agencies, and expanded enrollment scrutiny as key regulatory developments.
The Pennant Group, Inc. reported solid growth for the quarter ended March 31, 2026. Revenue rose to $285.4 million from $209.8 million a year earlier, driven by expansion in home health, hospice and senior living services.
Income from operations increased to $17.3 million versus $12.7 million, while net income attributable to Pennant grew to $8.5 million, or $0.24 per diluted share, up from $7.8 million, or $0.22. Segment Adjusted EBITDAR from Operations rose to $53.1 million, reflecting stronger performance in both home health and hospice and senior living.
Operating cash flow improved compared with the prior year but remained a modest use of cash at $3.4 million. Pennant ended the quarter with $4.9 million in cash, total assets of $956.5 million, long-term debt of $164.7 million, and total equity of $389.4 million.
The Pennant Group (PNTG) reported third‑quarter 2025 results with revenue of $229.0 million versus $180.7 million a year ago. Income from operations was $10.2 million compared to $10.8 million, and net income attributable to the company was $6.1 million versus $6.2 million. Diluted EPS was $0.17 versus $0.20.
Home Health and Hospice revenue reached $173.5 million and Senior Living $53.9 million. Segment Adjusted EBITDAR from Operations improved to $44.4 million, led by $29.1 million in Home Health and Hospice and $15.3 million in Senior Living. Year to date, operating cash flow was $27.3 million.
The company expanded through acquisitions in 2025, including part two of Signature Group (contributing $48.8 million revenue and $8.9 million operating income year to date) and additional home health deals. Cash was $2.3 million, long‑term debt was $26.0 million under the revolving credit facility, and total assets were $753.6 million. As of November 3, 2025, 34,593,720 common shares were outstanding. Subsequent to quarter end, Pennant closed a $146.5 million acquisition of home health, hospice, and home care locations and added a $100 million incremental term loan under its credit agreement.